Shire to Relocate More Than 500 Jobs to Lexington, MA
Shire plans to relocate more than 500 positions to Massachusetts from its Chesterbrook, PA, site and establish Lexington, MA, as the company’s US operational headquarters.
Shire plans to relocate more than 500 positions to Massachusetts from its Chesterbrook, PA, site and establish Lexington, MA, as the company’s US operational headquarters. The transition is a continuation of the company’s “One Shire” efficiency program and will streamline business globally through two principal locations-Massachusetts and Switzerland-with support from a limited number of regional and country-based offices around the world.
The company says simplifying operations in two principal locations will increase efficiencies; it expects to realize approximately $25 million in annual savings beginning in 2016. The site strategy will reportedly enable greater alignment and execution of priorities between the company’s commercial and R&D teams and strengthen collaboration and cross-development of employees. Shire plans to move employees in several phases beginning in the first quarter of 2015 and targets completion by the first quarter of 2016.
As previously announced, interim CFO James Bowling will be leaving Shire. Jeff Poulton, head of investor relations, will assume the role of interim CFO effective January 1, 2015. The CFO position will be based in Lexington.
Source: Shire
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
